Advertisement
FWBI 外匯新聞
First Wave BioPharma To Sell Niclosamide Program To Undisclosed Biopharmaceutical Company
Biopharmaceutical company First Wave BioPharma, Inc. (FWBI) announced Wednesday that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and related conditions to an undisclosed biopharmaceutical company.
RTTNews
|
527天前
First Wave BioPharma To Acquire ImmunogenX In All-stock Transaction
Biopharmaceutical company First Wave BioPharma, Inc. (FWBI) announced Monday that the company has signed a non-binding term sheet to acquire biotherapeutics company ImmunogenX in an all-stock transaction.
RTTNews
|
536天前
